Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
| Trades 15 | Longs Won 7/15 46% | Profit Factor 0.26 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $19,528.18 |
| Average Win $4,122.87 | Best Trade (Feb 14) $11,018.94 | Sharpe Ratio -19.94 |
| Average Loss -$13,829.03 | Worst Trade (Jul 27) -$71,459.28 | Z-Score -2.14 (100%) |
| Commissions $0 | Avg. Trade Length 2m 3w | Expectancy -$5,451.48 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | - | - | - | - | - | - | - | - | - | - |
| Consecutive Losing Trades | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
UNCY Unicycive Therapeutics Inc. | 3,690.85 | $19,487.71 | $18,232.82 | - | -$1,254.89 | -6.44% | -3.704% |